Treatment of snoring and sleep apnea syndrome with a removable mandibular advancement device in patients without TMD

• Autor(a) principal: Duarte, Eduardo Rollo
• Data de Publicação: 2012
• Outros Autores: Frigério, Maria Luiza M. A., Tavano, Orivaldo, Razuk, Paulo César [UNESP], Costa, Maria Rita de Cássia M., Martins, Carlos Henrique Ferreira, Ribeiro, Maurício Serejo, Betiol, Éderson A. G.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1590/S2176-94512012000200017; http://hdl.handle.net/11449/27170
• topic: Snoring; Obstructive sleep apnea; Mandibular advancement; Occlusal splints

INTRODUCTION: Among the sleep disorders reported by the American Academy of Sleep, the most common is obstructive sleep apnea-hypopnea syndrome (OSAHS), which is caused by difficulties in air passage and complete interruption of air flow in the airway. This syndrome is associated with increased morbidity and mortality in apneic individuals. OBJECTIVE: It was the objective of this paper to evaluate a removable mandibular advancement device as it provides a noninvasive, straightforward treatment readily accepted by patients. METHODS: In this study, 15 patients without temporomandibular disorders (TMD) and with excessive daytime sleepiness or snoring were evaluated. Data were collected by means of: Polysomnography before and after placement of an intraoral appliance, analysis of TMD signs and symptoms using a patient history questionnaire, muscle and TMJ palpation. RESULTS: After treatment, the statistical analysis (t-test, and the before and after test) showed a mean reduction of 77.6% (p=0.001) in the apnea-hypopnea index, an increase in lowest oxyhemoglobin saturation (p=0.05), decrease in desaturation (p=0.05), decrease in micro-awakenings or EEG arousals (p=0.05) and highly significant improvement in daytime sleepiness (p=0.005), measured by the Epworth Sleepiness Scale. No TMD appeared during the monitoring period. CONCLUSION: The oral device developed in this study was considered effective for mild to moderate OSAHS.